GlaxoSmithKline PLC Director/PDMR Shareholding (6576D)
20 Febbraio 2020 - 4:30PM
UK Regulatory
TIDMGSK
RNS Number : 6576D
GlaxoSmithKline PLC
20 February 2020
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr R Connor
==== ======================================= ===================================================
b) Position/status President, Global Vaccines
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 43,760
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms D Conrad
==== ======================================= ===================================================
b) Position/status SVP, Human Resources
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the Following the vesting of awards granted
transaction in 2017 under the Company's 2017 Performance
Share Plan, Ms Conrad received a cash amount
of approximately GBP152,000 (less applicable
tax withholding) which is equal to the
market value of the number of Ordinary
Shares which would otherwise have been
transferred to her.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 9,168
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-19
==== ======================================= ===================================================
f) Place of the N/A
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr J Ford
==== ======================================== ================================================
b) Position/status SVP & General Counsel
==== ======================================== ================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ================================================
b) Nature of the The sale of ADSs to meet tax liabilities
transaction on the vesting of awards granted in 2017
under the Company's 2017 Performance Share
Plan.
==== ======================================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ==================== =======================
$43.544 2,454
==================== =======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ====================================================
e) Date of the transaction 2020-02-18
==== ======================================== ================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr N Hirons
==== ======================================= ===================================================
b) Position/status SVP, Global Ethics & Compliance
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 16,122
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms S Jackson
==== ======================================= ===================================================
b) Position/status SVP, Global Communications & CEO Office
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 4,309
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr D Jackson
==== ======================================= =====================================================
b) Position/status PCA of Ms S Jackson (SVP, Global Communications
& CEO Office)
==== ======================================= =====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= =====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= =====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= =====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= =====================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= =====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================== ======================
GBP16.597 1,111
======================================================================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== =============================
e) Date of the transaction 2020-02-18
==== ======================================= =====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= =====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr B McNamara
==== ======================================== ================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ================================================
b) Nature of the The sale of ADSs to meet tax liabilities
transaction on the vesting of awards granted in 2017
under the Company's 2017 Performance Share
Plan.
==== ======================================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ==================== =======================
$43.544 33,055
==================== =======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ====================================================
e) Date of the transaction 2020-02-18
==== ======================================== ================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr L Miels
==== ======================================= ===================================================
b) Position/status President Global Pharmaceuticals
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 65,213
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr D Redfern
==== ======================================= ===================================================
b) Position/status Chief Strategy Officer
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 31,324
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr R Simard
==== ======================================= ===================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 4,309
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr P Thomson
==== ======================================= ===================================================
b) Position/status President, Global Affairs
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 21,650
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms D Waterhouse
==== ======================================= ===================================================
b) Position/status CEO of ViiV Healthcare
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 5,909
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms V Whyte
==== ======================================= ===================================================
b) Position/status Company Secretary
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ======================================= ===================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the vesting of awards granted
in 2017 under the Company's 2017 Performance
Share Plan.
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= =====================
GBP16.597 4,309
====================================================================== =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
=================================================================== ============================
e) Date of the transaction 2020-02-18
==== ======================================= ===================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ======================================= ===================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEBLFLBLLLBBK
(END) Dow Jones Newswires
February 20, 2020 10:30 ET (15:30 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
